세계의 류마티스 관절염 치료제 시장 규모, 점유율 및 동향 분석 보고서 : 분자별, 판매 채널별, 지역별, 부문별 예측(2024-2030년)

Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report By Molecule (Pharmaceuticals, Biopharmaceuticals), By Sales Channel (Prescription, OTC), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,242,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,627,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,398,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

류마티스 관절염 치료제 시장 성장 및 동향 :

Grand View Research, Inc.의 최신 조사에 따르면, 세계 류마티스 관절염 치료제 시장 규모는 2030년까지 363억 9,000만 달러에 달했고, 2024-2030년간 연평균 5.93%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.

시장을 이끄는 주요 동향으로는 새로운 생물학적 제제의 가용성, 잠재적인 임상 파이프라인 후보물질 증가, 고령화 인구 증가 등이 있습니다. 따라서 보다 안전한 약물의 가용성과 인지도가 높아짐에 따라 류마티스 관절염 치료제 시장의 성장이 가속화될 것으로 예상됩니다.

류마티스 관절염은 전 세계 인구의 약 1%가 앓고 있습니다. 이 질환은 관절의 통증, 부종, 뻣뻣함 등 다양한 증상을 나타내며, 일반적으로 만성적인 통증을 동반하고 일상적인 활동을 방해합니다. 이 질환이 장기간 지속되면 환자의 운동 능력을 방해하고 관절에 영구적인 손상을 초래할 수 있습니다. 이 질환을 치료하지 않고 방치하면 운동 기능 장애와 인공관절 치환술의 위험에 노출될 수 있습니다.

관절염 재단에 따르면, 미국 65세 이하 인구의 64%가 관절염을 앓고 있으며, 이 질환의 유병률 증가, 생물학적 제제 및 바이오시밀러의 존재, 명확한 규제 가이드라인은 시장에 활력을 불어넣을 준비가 되어 있습니다. 질병 송금 치료에 대한 인식 증가와 선진국의 의료비 증가는 매출 성장을 가속할 것으로 추정됩니다.

현재 류마티스 관절염 치료에는 JAK 억제제, IL-6 길항제와 같은 새로운 생물학적 제제 외에도 비스테로이드성 항염증제(NSAIDs), 부신피질 스테로이드와 같은 제네릭 의약품이 있으며, 높은 효과로 인해 선진국에서 널리 사용되고 있습니다. 인플릭시맙과 아달리무맙의 바이오시밀러와 같은 신제품 출시는 시장에 유리하게 작용할 것으로 예상됩니다. 또한 Eli Lilly의 Olumiant와 AbbVie의 Upadacitinib은 질병의 재발 가능성을 감소시킬 것으로 예상됩니다.

류마티스 관절염 치료제 시장 보고서 하이라이트

• 바이오 의약품 부문이 시장을 주도하며 2023년 세계 매출의 88.73%를 차지할 것으로 예상됩니다. 바이오 의약품은 생물학적 자원에서 제조, 추출 및 합성되는 고분자 의약품입니다.
• 2023년에는 처방약이 89.64% 시장 점유율로 시장을 주도할 것으로 예상됩니다. 류마티스 전문의의 진료가 증가함에 따라 처방약 부문은 예측 기간 동안 류마티스 관절염 치료 시장에서 우위를 유지할 것으로 예상됩니다.
• 북미 류마티스 관절염 치료 시장은 2023년 52.31%의 점유율을 차지했습니다. 이 지역 시장은 인구 통계학적 변화, 의료 연구 발전, 규제 변화, 개인 맞춤형 의료에 대한 중요성 증가 등으로 인해 성장과 발전을 거듭하고 있습니다.
• 아시아태평양의 류마티스 관절염 치료 시장은 류마티스 관절염 유병률 증가, 의료 인프라 개선, 치료 옵션의 발전으로 인해 큰 성장세를 보이고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 류마티스 관절염 치료 시장 변수, 동향, 범위

• 류마티스 관절염 치료 시장 계통 전망
  • 상위 시장 전망
  • 보조 시장 전망 - 골관절염 치료 시장
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 류마티스 관절염 치료 시장 분석 툴
  • Porter의 Five Forces 분석
  • PESTLE 분석

제4장 류마티스 관절염 치료 시장 분석, 분자별, 2018-2030년(100만 달러)

• 류마티스 관절염 치료 : 분자 변동 분석
• 류마티스 관절염 치료 시장 분석 : 분자별
  • 바이오의약품
  • 의약품

제5장 류마티스 관절염 치료 시장 분석, 판매채널별, 2018-2030년(100만 달러)

• 류마티스 관절염 치료 : 판매채널 변동 분석
• 류마티스 관절염 치료 시장 분석 : 판매채널별
  • 처방약
  • 시판약(OTC)

제6장 류마티스 관절염 치료 시장 : 분자별, 판매채널별 지역 추정·동향 분석

• 류마티스 관절염 치료 시장 : 지역별 전망
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제7장 경쟁 구도

• 시장 진출기업 분류
• 주요 기업 개요
  • AbbVie, Inc.
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Pfizer, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • UCB SA
  • Johnson &Johnson Services, Inc.
  • AG Amgen, Inc.
  • Lilly(Eli Lilly and Company)

LSH

영문 목차

영문목차

Rheumatoid Arthritis Therapeutics Market Growth & Trends:

The global rheumatoid arthritis therapeutics market size is expected to reach USD 36.39 billion by 2030, expanding at a CAGR of 5.93% from 2024 to 2030, according to a new study by Grand View Research, Inc. expanding at a CAGR of 4.6% during the forecast period. Some of the key trends driving the market are availability of novel biologics, increase in potential clinical pipeline candidates, and rise in aging population. Thus, growing availability and awareness of safer drugs are projected to escalate rheumatoid arthritis drugs market growth.

Rheumatoid arthritis affects approximately 1% of the global population. The condition has different symptoms such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient's mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and risk of joint replacement.

Growing prevalence of the disease, presence of biologics & biosimilars, and well-defined regulatory guidelines are poised to provide a fillip to the market. According to the Arthritis Foundation, 64% of the population within the age group of 65 is likely to suffer from arthritis in U.S. Increasing awareness regarding disease remittance therapies and rising healthcare expenditure in developed regions are estimated to promote revenue growth.

Current treatment for rheumatoid arthritis includes generic pharmaceuticals such as NSAIDs and corticosteroids along with novel biologics such as JAK inhibitors and IL-6 antagonists, which are widely used in developed countries due to their high effectiveness. New product launches such as Infliximab and Adalimumab biosimilars are anticipated to work in favor of the market. Moreover, Eli Lilly's Olumiant and AbbVie's Upadacitinib are expected to cut down chances of disease remittance.

Rheumatoid Arthritis Therapeutics Market Report Highlights:

• Biopharmaceuticals segment led the market and accounted for 88.73% of the global revenue in 2023. Biopharmaceuticals are large-molecule drugs that are manufactured, extracted, and synthesized from biological sources.
• Prescription led the market with a market share of 89.64% in 2023. As rheumatologist consultations rise, the prescription segment is expected to remain dominant in the market for rheumatoid arthritis medications over the forecast period.
• North America rheumatoid arthritis therapeutics market accounted for 52.31% share in 2023. The regional market continues to grow and evolve, driven by demographic shifts, advancements in medical research, regulatory changes, and an increasing emphasis on personalized healthcare.
• The Asia Pacific rheumatoid arthritis therapeutics market is experiencing significant growth, driven by the increasing prevalence of rheumatoid arthritis, improving healthcare infrastructure, and advancements in treatment options.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Molecule
  • 1.2.2. Sales channel
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Molecule and Sales Channel Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Rheumatoid Arthritis Therapeutics Market Variables, Trends, and Scope

• 3.1. Rheumatoid Arthritis Therapeutics Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary market outlook - Osteoarthritis Therapeutics Market
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of rheumatoid arthritis
    • 3.2.1.2. Launch of novel therapeutic agents
    • 3.2.1.3. Shift in treatment from the relief of symptoms to targeted therapy
    • 3.2.1.4. Favorable reimbursement policies
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of rheumatoid arthritis therapeutic drugs
    • 3.2.2.2. Side effects and adverse reactions
• 3.3. Rheumatoid Arthritis Therapeutics Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTLE Analysis

Chapter 4. Rheumatoid Arthritis Therapeutics Market Analysis, by Molecule, 2018 - 2030 (USD Million)

• 4.1. Rheumatoid Arthritis Therapeutics: Molecule Movement Analysis
• 4.2. Rheumatoid Arthritis Therapeutics Market Analysis, by Molecule Market (USD Million)
  • 4.2.1. Biopharmaceuticals
    • 4.2.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.2. Biologics
    • 4.2.1.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.2.2. TNF-a antagonists
    • 4.2.1.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.2.3. T-cell inhibitors
    • 4.2.1.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.2.4. CD20 antigen
    • 4.2.1.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.2.5. JAK inhibitors
    • 4.2.1.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.2.6. anti-IL6 biologics
    • 4.2.1.2.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.3. Biosimilars
    • 4.2.1.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.3.2. CD20 antigen
    • 4.2.1.3.3. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.1.3.4. TNF-a antagonists
    • 4.2.1.3.5. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.2.2. Pharmaceuticals
    • 4.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2.2. NSAIDs
    • 4.2.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2.3. Analgesics
    • 4.2.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2.4. DMARDs
    • 4.2.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2.5. Glucocorticoids
    • 4.2.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Rheumatoid Arthritis Therapeutics Market Analysis, by Sales Channel, 2018 - 2030 (USD Million)

• 5.1. Rheumatoid Arthritis Therapeutics: Sales Channel Movement Analysis
• 5.2. Rheumatoid Arthritis Therapeutics Market Analysis, by Sales Channel Market (USD Million)
  • 5.2.1. Prescription
    • 5.2.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.2.2. Over-the-Counter (OTC)
    • 5.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Rheumatoid Arthritis Therapeutics Market: Regional Estimates and Trend Analysis by Molecule, by Sales Channel

• 6.1. Rheumatoid Arthritis Therapeutics Market: Regional Outlook
• 6.2. North America
  • 6.2.1. North America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.2.2. U.S.
    • 6.2.2.1. Key Country Dynamics
    • 6.2.2.2. Target Disease Prevalence
    • 6.2.2.3. U.S. Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2.4. Competitive/Market Scenario
    • 6.2.2.5. Regulatory Framework
    • 6.2.2.6. Reimbursement scenario
  • 6.2.3. Canada
    • 6.2.3.1. Key Country Dynamics
    • 6.2.3.2. Target Disease Prevalence
    • 6.2.3.3. Canada Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3.4. Competitive/Market Scenario
    • 6.2.3.5. Regulatory Framework
    • 6.2.3.6. Reimbursement Scenario
  • 6.2.4. Mexico
    • 6.2.4.1. Key Country Dynamics
    • 6.2.4.2. Target Disease Prevalence
    • 6.2.4.3. Mexico Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4.4. Competitive/Market Scenario
    • 6.2.4.5. Regulatory Framework
    • 6.2.4.6. Reimbursement Scenario
• 6.3. Europe
  • 6.3.1. Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.2. UK
    • 6.3.2.1. Key Country Dynamics
    • 6.3.2.2. Target Disease Prevalence
    • 6.3.2.3. UK Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2.4. Competitive/Market Scenario
    • 6.3.2.5. Regulatory Framework
    • 6.3.2.6. Reimbursement Scenario
  • 6.3.3. Germany
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Target Disease Prevalence
    • 6.3.3.3. Germany Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3.4. Competitive/Market Scenario
    • 6.3.3.5. Regulatory Framework
    • 6.3.3.6. Reimbursement Scenario
  • 6.3.4. France
    • 6.3.4.1. Key Country Dynamics
    • 6.3.4.2. Target Disease Prevalence
    • 6.3.4.3. France Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4.4. Competitive/Market Scenario
    • 6.3.4.5. Regulatory Framework
    • 6.3.4.6. Reimbursement Scenario
  • 6.3.5. Spain
    • 6.3.5.1. Key Country Dynamics
    • 6.3.5.2. Target Disease Prevalence
    • 6.3.5.3. Spain Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5.4. Competitive/Market Scenario
    • 6.3.5.5. Regulatory Framework
    • 6.3.5.6. Reimbursement Scenario
  • 6.3.6. Italy
    • 6.3.6.1. Key Country Dynamics
    • 6.3.6.2. Target Disease Prevalence
    • 6.3.6.3. Italy Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6.4. Competitive/Market Scenario
    • 6.3.6.5. Regulatory Framework
    • 6.3.6.6. Reimbursement Scenario
  • 6.3.7. Denmark
    • 6.3.7.1. Key Country Dynamics
    • 6.3.7.2. Target Disease Prevalence
    • 6.3.7.3. Denmark Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7.4. Competitive/Market Scenario
    • 6.3.7.5. Regulatory Framework
    • 6.3.7.6. Reimbursement Scenario
  • 6.3.8. Sweden
    • 6.3.8.1. Key Country Dynamics
    • 6.3.8.2. Target Disease Prevalence
    • 6.3.8.3. Sweden Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8.4. Competitive/Market Scenario
    • 6.3.8.5. Regulatory Framework
    • 6.3.8.6. Reimbursement Scenario
  • 6.3.9. 6.3.9 Norway
    • 6.3.9.1. Key Country Dynamics
    • 6.3.9.2. Target Disease Prevalence
    • 6.3.9.3. Norway Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9.4. Competitive/Market Scenario
    • 6.3.9.5. Regulatory Framework
    • 6.3.9.6. Reimbursement Scenario
    • 6.3.9.7. Rest of Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Asia Pacific
  • 6.4.1. Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. Japan
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Target Disease Prevalence
    • 6.4.2.3. Japan Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2.4. Competitive/Market Scenario
    • 6.4.2.5. Regulatory Framework
    • 6.4.2.6. Reimbursement Scenario
  • 6.4.3. China
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. China Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3.4. Competitive/Market Scenario
    • 6.4.3.5. Regulatory Framework
    • 6.4.3.6. Reimbursement Scenario
  • 6.4.4. India
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. India Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4.4. Competitive/Market Scenario
    • 6.4.4.5. Regulatory Framework
    • 6.4.4.6. Reimbursement Scenario
  • 6.4.5. Australia
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Target Disease Prevalence
    • 6.4.5.3. Australia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5.4. Competitive/Market Scenario
    • 6.4.5.5. Regulatory Framework
    • 6.4.5.6. Reimbursement Scenario
  • 6.4.6. Thailand
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Target Disease Prevalence
    • 6.4.6.3. Thailand Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6.4. Competitive/Market Scenario
    • 6.4.6.5. Regulatory Framework
    • 6.4.6.6. Reimbursement Scenario
  • 6.4.7. South Korea
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Target Disease Prevalence
    • 6.4.7.3. South Korea Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7.4. Competitive/Market Scenario
    • 6.4.7.5. Regulatory Framework
    • 6.4.7.6. Reimbursement Scenario
    • 6.4.7.7. Rest of Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.5. Latin America
  • 6.5.1. Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. Brazil
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Target Disease Prevalence
    • 6.5.2.3. Brazil Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2.4. Competitive/Market Scenario
    • 6.5.2.5. Regulatory Framework
    • 6.5.2.6. Reimbursement Scenario
  • 6.5.3. Argentina
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Argentina Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3.4. Competitive/Market Scenario
    • 6.5.3.5. Regulatory Framework
    • 6.5.3.6. Reimbursement Scenario
    • 6.5.3.7. Rest of Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. MEA
  • 6.6.1. MEA Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. South Africa
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Target Disease Prevalence
    • 6.6.2.3. South Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2.4. Competitive/Market Scenario
    • 6.6.2.5. Regulatory Framework
    • 6.6.2.6. Reimbursement Scenario
  • 6.6.3. Saudi Arabia
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Saudi Arabia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3.4. Competitive/Market Scenario
    • 6.6.3.5. Regulatory Framework
    • 6.6.3.6. Reimbursement Scenario
  • 6.6.4. UAE
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Target Disease Prevalence
    • 6.6.4.3. UAE Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4.4. Competitive/Market Scenario
    • 6.6.4.5. Regulatory Framework
    • 6.6.4.6. Reimbursement Scenario
  • 6.6.5. Kuwait
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Target Disease Prevalence
    • 6.6.5.3. Kuwait Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5.4. Competitive/Market Scenario
    • 6.6.5.5. Regulatory Framework
    • 6.6.5.6. Reimbursement Scenario
  • 6.6.6. Rest of MEA Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Key Company Profiles
  • 7.2.1. AbbVie, Inc.
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. Boehringer Ingelheim International GmbH
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Novartis AG
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Regeneron Pharmaceuticals Inc.
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Pfizer, Inc.
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Bristol-Myers Squibb Company
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. F. Hoffmann-La Roche Ltd.
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. UCB S.A.
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. Johnson & Johnson Services, Inc.
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. AG Amgen, Inc.
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. Lilly (Eli Lilly and Company)
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives

관련자료